

Investor News  
No. 2/2014

## Notice of release date and conference call for Zealand's Full Year results and Annual Report for 2013

– ***The company invites for a conference call and live audio webcast to be hosted by management on Thursday 20 March 2014 at 15:00 CET/ 10:00 EDT***

Copenhagen, 12 March 2014 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") will announce its Full Year results and publish the Annual Report for 2013 on Thursday, 20 March 2013 in the morning.

### **Conference call – Thursday, 20 March 2014 at 15:00 CET/ 10:00 EDT**

On the day of release, David Solomon, President and Chief Executive Officer, Mats Blom, Chief Financial Officer and Hanne Leth Hillman, Vice President and Head of IR and Corporate Communications, will host a conference call at 15:00 CET/ 10:00 EDT to present the Full Year results and Annual Report for 2013, followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access	+45 3272 8018
UK and international	+44 (0) 1452 555131
US (free dial-in)	+1 866 682 8490

A live audio cast of the call including an accompanying slide presentation will be available via the following link, <http://www.media-server.com/m/p/nvqt76ii>, which can also be accessed from the Investor section of the company's website ([www.zealandpharma.com](http://www.zealandpharma.com)). Participants are advised to register for the audio cast approximately 10 minutes before the start.

A replay of the event will also be made available from the Investor section of Zealand's website following the call.

\*\*\*



**For further information, please contact:**

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications  
Tel: +45 5060 3689, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

**About Zealand**

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia<sup>®</sup>) is approved in several countries globally, including Europe and Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the pivotal Phase 3 clinical program for the Lantus<sup>®</sup>/Lyxumia<sup>®</sup> combination product (LixiLan).

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com)

Follow us on Twitter @ZealandPharma